Drug Profile
Research programme: oncology kinase inhibitors - Arrien Pharmaceuticals
Alternative Names: ARN-1032; ARN-3015; ARN-3016; ARN-3020; ARN-5032; ARN-7016Latest Information Update: 30 Dec 2022
Price :
$50
*
At a glance
- Originator Arrien Pharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action Salt-inducible kinase-2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 30 Dec 2022 NDR batch #27: The drug candidates are no longer available on company website; hence opted for discontinuation
- 30 Dec 2022 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Cancer in USA